Posts

Posted on

CORRECTING and REPLACING Source Capital, Inc. Declares Monthly Distributions on Common Stock

CORRECTING and REPLACING Source Capital, Inc. Declares Monthly Distributions on Common Stock

LOS ANGELES–(BUSINESS WIRE)–
The first Record Date in table of release dated August 9, 2021, should read: September 16, 2021 (instead of September 6, 2021).

The updated release reads:

SOURCE CAPITAL, INC. DECLARES MONTHLY DISTRIBUTIONS ON COMMON STOCK

The Board of Directors of Source Capital, Inc. (NYSE: SOR) (the “Fund”), today approved maintaining the Fund’s regular monthly distribution rate for each of the next three months as follows:

Month

Cents per

Common Share

Record Date

Payable Date

September 2021

18.5

September 16, 2021

September 30, 2021

October 2021

18.5

October 18, 2021

October 29, 2021

November 2021

18.5

November 16, 2021

November 30, 2021

About Source Capital, Inc.

Source Capital, Inc. is a closed-end investment company managed by First Pacific Advisors, LP. Its shares are listed on the New York Stock Exchange under the symbol “SOR.” The investment objective of the Fund is to seek maximum total return for shareholders from both capital appreciation and investment income to the extent consistent with protection of invested capital. The Fund may invest in longer duration assets like dividend paying equities and illiquid assets like private loans in pursuit of its investment objective and is thus intended only for those investors with a long-term investment horizon (greater than or equal to ~5 years).

You can obtain additional information by visiting the website at www.fpa.com, by email at [email protected], toll free by calling 1-800-982-4372, or by contacting the Fund in writing.

Important Disclosures

You should consider the Fund’s investment objectives, risks, and charges and expenses carefully before you invest.

Distributions may include ordinary income, net capital gains and/or returns of capital. Generally, a return of capital would occur when the amount distributed by the Fund includes a portion of (or is comprised entirely of) your investment in the Fund in addition to (or rather than) your pro-rata portion of the Fund’s net income or capital gains. The Fund’s distributions in any period may be more or less than the net return earned by the Fund on its investments, and therefore should not be used as a measure of performance or confused with “yield” or “income.” A return of capital is not taxable; rather it reduces a shareholder’s tax basis in his or her shares of the Fund. If the Fund estimates that a portion of its distribution may be comprised of amounts from sources other than net investment income, the Fund will notify shareholders of the estimated composition of such distribution through a separate written Section 19 notice. Such notices are provided for informational purposes only, and should not be used for tax reporting purposes. Final tax characteristics of all Fund distributions will be provided on Form 1099-DIV, which is mailed after the close of the calendar year.

It is important to note that differences exist between the Fund’s daily internal accounting records and practices, the Fund’s financial statements prepared in accordance with U.S. GAAP, and recordkeeping practices under income tax regulations. Please see the Fund’s most recent shareholder reports for more detailed tax information.

The Fund’s distribution rate may be affected by numerous factors, including changes in realized and projected market returns, Fund performance, and other factors. There can be no assurance that a change in market conditions or other factors will not result in a change in the Fund’s distribution rate at a future time.

As with any stock, the price of the Fund’s common shares will fluctuate with market conditions and other factors. Shares of closed-end management investment companies frequently trade at a price that is less than (a “discount”) or more than (a “premium”) their net asset value. If the Fund’s shares trade at a premium to net asset value, there is no assurance that any such premium will be sustained for any period of time and will not decrease, or that the shares will not trade at a discount to net asset value thereafter.

The Fund’s daily New York Stock Exchange closing market prices, net asset values per share, as well as other information, including updated portfolio statistics and performance are available by visiting the website at https://fpa.com/funds/overview/source-capital, by email at [email protected], toll free by calling 1-800-279-1241 (option 1), or by contacting the Fund in writing.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful under the securities laws of any such state. In the event of a tender offer, there may be tax consequences for a stockholder. For example, a stockholder may owe capital gains taxes on any increase in the value of the shares over your original cost.

Investments, including investments in closed-end funds, carry risks and investors may lose principal value. Capital markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. It is important to remember that there are risks inherent in any investment and there is no assurance that any investment or asset class will provide positive performance over time. Value style investing presents the risk that the holdings or securities may never reach our estimate of intrinsic value because the market fails to recognize what the portfolio management team considers the true business value or because the portfolio management team has misjudged those values. In addition, value style investing may fall out of favor and underperform growth or other style investing during given periods. Non-U.S. investing presents additional risks, such as the potential for adverse political, currency, economic, social or regulatory developments in a country, including lack of liquidity, excessive taxation, and differing legal and accounting standards. Non-U.S. securities, including American Depository Receipts (ADRs) and other depository receipts, are also subject to interest rate and currency exchange rate risks.

Fixed income instruments are subject to interest rate, inflation and credit risks. Such investments may be secured, partially secured or unsecured and may be unrated, and whether or not rated, may have speculative characteristics. The market price of the Fund’s fixed income investments will change in response to changes in interest rates and other factors. Generally, when interest rates rise, the values of fixed income instruments fall, and vice versa. Certain fixed income instruments are subject to prepayment risk and/or default risk.

Private placement securities are securities that are not registered under the federal securities laws, and are generally eligible for sale only to certain eligible investors. Private placements may be illiquid, and thus more difficult to sell, because there may be relatively few potential purchasers for such investments, and the sale of such investments may also be restricted under securities laws.

The Fund may use leverage. While the use of leverage may help increase the distribution and return potential of the Fund, it also increases the volatility of the Fund’s net asset value (NAV), and potentially increases volatility of its distributions and market price. There are costs associated with the use of leverage, including ongoing dividend and/or interest expenses. There also may be expenses for issuing or administering leverage. Leverage changes the Fund’s capital structure through the issuance of preferred shares and/or debt, both of which are senior to the common shares in priority of claims. If short-term interest rates rise, the cost of leverage will increase and likely will reduce returns earned by the Fund’s common stockholders.

This material has been distributed for informational purposes only and should not be considered as investment advice or a recommendation of any particular security, strategy or investment product. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission.

Tucker Hewes

Hewes Communications, Inc.

[email protected]

212-207-9451

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

Crown Royal Regal Apple And Harlem’s Fashion Row Support Designers Of Color By Awarding Grants During New York Fashion Week

Harlem’s Fashion Row’s nonprofit, ICON360, and Crown Royal Regal Apple bestow four grants to Black designers during Tuesday’s Harlem Fashion Row Style Awards; Guests at official after-party purchased designs directly from ‘Designer’s Row’

PR Newswire

NEW YORK, Sept. 8, 2021 /PRNewswire/ — Crown Royal Regal Apple and Harlem’s Fashion Row (HFR) – a premier agency creating a bridge between brands and designers of color in the fashion industry — united on Tuesday evening for HFR’s New York Fashion Week Style Awards, Runway Show and After-Party. Committed to empowering the next generation of artists and creatives, Crown Royal Regal Apple collaborated with HFR’s 501(c)(3) nonprofit, ICON360, to award four $10,000 grants to emerging Black designers that help push culture forward in innovative, new ways.

Experience the interactive Multimedia News Release here: https://www.multivu.com/players/English/8946851-crown-royal-regal-apple-harlem-fashion-row-style-awards-grants-to-black-designers/

Crown Royal Regal Apple and Harlem’s Fashion Row (HFR) united for an evening of Regal Renaissance during HFR’s New York Fashion Week Style Awards, Runway Show and After-Party on Tuesday, September 7.

Ahead of the evening at 137th Street & 7th Avenue, Crown Royal Regal Apple outfitted Harlem’s Fashion Row Runway Show with its own photo experience and sneaker cleaning booth to help guests stay fresh ahead of the night. Further into the evening, the Style Awards peaked with the presentation of the 2021 Royal Icon Awards presented by Crown Royal Regal Apple & ICON360, a grant awarded to each creator showcasing their new lines as a part of the Runway Show.

“Crown Royal Regal Apple, in partnership with Harlem’s Fashion Row and ICON360, is continuing its mission to support artists and creators who, in fresh, new ways, are shaping culture,” said Nicola Heckles, Vice President at Crown Royal. “These grants not only celebrate each designer but also directly supports their work in a meaningful way, sharing our platform to support the visibility and successive sales of the designs they’ve shown tonight.”

Crown Royal Regal Apple and HFR’s Icon360 grant recipients include: TIER founders Nigeria Ealey, Esaïe Jean Simon and Victor James, who strive to impact, inspire, create and communicate their individual and collective stories through fashion and experiences; Johnathan Hayden, whose work has contributed to exploring meaningful applications of technology in fashion; Shawn Pean, founder of luxury menswear brand June79 that aims to redefine luxury among a new renaissance consumer; and Charles Harbison, Creative Director for modern luxury lifestyle brand Harbison Studio.

“Crown Royal Regal Apple and Harlem’s Fashion Row share the same charge to champion and uplift creators in multicultural communities,” said Brandice Daniel, CEO of Harlem’s Fashion Row. “ICON360 was created specifically to fund designers of color who, with monetary support, can continue leading the revival of Black culture that is happening right now in places like Harlem and across the country.”

Crown Royal Regal Apple also hosted the official after-party with deejays Kitty Ca$h and Cory Townes both spinning while guests of legal drinking age sipped Crown Apple cocktails. Each collection from the newly knighted crisp culture grant recipients was also displayed as an extension of their earlier debut. Guests were able to purchase the designs directly via QR codes at the display dubbed ‘Designer’s Row’.

Infused with Regal Gala Apples, Crown Royal Regal Apple is a smooth, delicious tasting whisky that is best enjoyed responsibly as a chilled shot, on the rocks or in a cocktail. Crown Royal Regal Apple invites you to raise a glass to all crisp culture creators in our communities and remember to drink responsibly.

About Crown Royal
Crown Royal Canadian Whisky is the number-one selling Canadian whisky brand in the world and has a tradition as long and distinctive as its taste. Specially blended to commemorate a grand tour of Canada made by King George VI and Queen Elizabeth of Great Britain in 1939, Crown Royal’s smooth, elegant flavor and gift-worthy presentation reflect its regal origins – it is considered the epitome of Canadian whisky. For more information, visit crownroyal.com. Crown Royal encourages all consumers to please enjoy responsibly.

About Diageo North America
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Crown Royal, Bulleit and Buchanan’s whiskies, Smirnoff, Cîroc and Ketel One vodkas, Casamigos, DeLeon and Don Julio tequilas, Captain Morgan, Baileys, Tanqueray and Guinness.

Diageo is listed on both the New York Stock Exchange (NYSE: DEO) and the London Stock Exchange (LSE: DGE) and their products are sold in more than 180 countries around the world.

For more information about Diageo, their people, brands, and performance, visit diageo.com. Visit Diageo’s global responsible drinking resource, DRINKiQ.com, for information, initiatives, and ways to share best practice. Follow at Twitter and Instagram for news and information about Diageo North America: @Diageo_NA.

About Harlem’s Fashion Row
Founded in 2007 by Brandice Daniel, the organization supports emerging talent and provides a platform for underrepresented African American and Latino designers. Harlem’s Fashion Row (HFR) engages audiences and aligns brand partners with emerging designers of color in Fashion. HFR’s mission is to discover and showcase the emerging talent of color through a platform of national events and customized multi-platform programs. The organization initiates innovative events which attract a multitude of diverse influencers connected to the fashion industry. Their objective is to provide real business opportunities to people of color in fashion to showcase their skills and abilities in an industry, which is often inaccessible to this group. To learn more, please visit harlemsfashionrow.com.

About ICON 360
The Mission of ICON360 is to create equitable opportunities in the fashion industry by providing resources for HBCUs and Black designers and creatives. The non-profit (a subsidiary of Harlem Fashion Row) offers financial grants as well as developmental and advisory programs that support marginalized talent. ICON360 brings fashion industry stakeholders together to secure equity for established and emerging Black designers and creatives. The organization seeks to fill voids created by systemic barriers and inequitable practices that have excluded Black talent from professional advancement. To learn more, please visit hfricon360.com.

MEDIA CONTACTS:

Kyra Zeller


DIAGEO
[email protected]

Kait Sheppard

TAYLOR
[email protected]

Frances Armand

HARLEM’S FASHION ROW
[email protected]

Committed to empowering the next generation of artists and creatives, Crown Royal Regal Apple awarded design grants during the Style Awards to four creators, including Charles Harbison of Harbison Studio, showing their new lines as a part of the runway show.

 

Crown Royal Regal Apple showed up ahead of the colorful evening of Regal Renaissance with a 360 degree photo experience and sneaker cleaning booth to help guests stay fresh all night.

 

Crown Royal Regal Apple celebrates Black excellence and designers who were awarded a $10,000 grant and a customized Crown Royal bottle during HFR’s Style Awards at New York Fashion Week.

 

During the Crown Royal Regal Apple x Harlem’s Fashion Row after-party, deejay Kitty Ca$h spinned into the evening while guests sipped Crown Apple cocktails.

 

Crown Royal after-party guests also perused pieces from each designer’s collection from the Harlem’s Fashion Row Runway Show, all of which were available for purchase via custom QR codes.

 

Cision View original content:https://www.prnewswire.com/news-releases/crown-royal-regal-apple-and-harlems-fashion-row-support-designers-of-color-by-awarding-grants-during-new-york-fashion-week-301371384.html

SOURCE Crown Royal

Posted on

The Boston Beer Company Launches New “Bevy Long Drink”

Nordic-Inspired Sparkling Refresher Hits Shelves Nationwide This November in Two Styles

PR Newswire

BOSTON, Sept. 8, 2021 /PRNewswire/ — The Boston Beer Company today announced the launch of Bevy Long Drink, a new, refreshing beverage inspired by the national cocktail of Finland, the “Long Drink.”  Bevy Long Drink will hit shelves in early November in two flavors: Sparkling Citrus Refresher and Sparkling Berry Refresher.

Bevy’s new sparkling citrus refresher is made from a delicious and easy-drinking blend of citrus flavors and wild juniper berries for an exceptionally thirst-quenching beverage that’s perfect for any occasion. Bevy Long Drink’s initial styles are sweet, tart, refreshingly packed with flavor, and 5.8% ABV.

“Drinkers are searching for the ultimate in refreshment, but also don’t want to sacrifice taste. That’s where Bevy Long Drink comes in,” said Lesya Lysyj, The Boston Beer Company’s Chief Marketing Officer.  “It’s cocktail-inspired, easy to drink, and full-flavored, yet highly refreshing unlike any beer or pre-mixed cocktail out there.”

What is a “Long drink”?
Long Drink is a traditional Finnish cocktail that traditionally consists of gin, grapefruit soda, and tonic. The drink was first created when the Finnish government commissioned a refreshing cocktail to serve guests attending the 1952 Summer Olympics in Helsinki.

While inspired by the traditional cocktail, Bevy Long Drink will be the first Long Drink inspired beverage available in the U.S. without spirits.  Bevy Long Drink is made with an original malt base containing natural flavors and wild juniper berries.

Lysyj continued, “The Long Drink cocktail is Finland’s best-kept secret, but it’s typically made with gin. Bevy Long Drink is our signature spin on this classic.  We developed a cocktail-inspired recipe, with all the citrus flavors and wild juniper berries, and made it ready-to-drink from a can. You get all the refreshing citrus flavor without the gin. But the best part is that you don’t have to fly to Finland. You can just pick up a 6-pack at the store.”

Boston Beer, maker of other industry leading alcohol beverages Samuel Adams beer, Twisted Tea, Truly Hard Seltzer, Angry Orchard, and Dogfish Head beer plans to continue its proven track record of innovation to bring Finland’s best kept secret to US drinkers in early November, in 6-packs and 12-packs (12oz cans) and single-serve 24oz cans. 

About The Boston Beer Company:
The Boston Beer Company, Inc. (NYSE: SAM) began in 1984 brewing Samuel Adams beer and the Samuel Adams brand is currently recognized as one of the largest and most respected craft beer brands.  Our portfolio of brands also includes Truly Hard Seltzer, Twisted Tea, Angry Orchard Hard Cider and Dogfish Head Brewery as well as other craft beer brands such as Angel City Brewery and Coney Island Brewing. For more information, please visit our investor relations website at www.bostonbeer.com, which includes links to all of our respective brand websites.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-boston-beer-company-launches-new-bevy-long-drink-301371334.html

SOURCE The Boston Beer Company, Inc.

Posted on

Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Citius to highlight addition of Phase 3 cancer immunotherapy to its late-stage pipeline

PR Newswire

CRANFORD, N.J., Sept. 8, 2021 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

The presentation video will be available for viewing on demand starting at 7:00 am ET on Monday, September 13th. Investors may register for the conference at the event website. The archived webcast will be available for 90 days after the event and will be accessible on the Citius website.

Myron Holubiak, President and Chief Executive Officer of Citius, and Dr. Myron Czuczman, Chief Medical Officer of Citius, will discuss the Company’s expanded pipeline and near-term catalysts.

About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial.  Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19.  For more information, please visit www.citiuspharma.com.

Investor Relations for Citius Pharmaceuticals:

Ilanit Allen

Vice President, Corporate Communications and Investor Relations
T: 908-967-6677 x113
E: [email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-september-13-15-301369833.html

SOURCE Citius Pharmaceuticals, Inc.

Posted on

Lumen Technologies to Present at the Bank of America Media, Communications & Entertainment Conference

PR Newswire

DENVER, Sept. 8, 2021 /PRNewswire/ — Shaun Andrews, executive vice president and chief marketing officer at Lumen Technologies (NYSE: LUMN), will present at the Bank of America 2021 Media, Communications & Entertainment Conference on Sept. 13. The presentation is scheduled to begin at 10:20 a.m. EDT.

Webcast information for the investor presentation can be found on the Lumen Investor Relations website at https://ir.lumen.com/events-and-presentations.

About Lumen Technologies

Lumen is guided by our belief that humanity is at its best when technology advances the way we live and work. With approximately 450,000 route fiber miles and serving customers in more than 60 countries, we deliver the fastest, most secure platform for applications and data to help businesses, government and communities deliver amazing experiences.

Learn more about the Lumen network, edge cloud, security, communication and collaboration solutions and our purpose to further human progress through technology at news.lumen.com/home, LinkedIn: /lumentechnologies, Twitter: @lumentechco, Facebook: /lumentechnologies, Instagram: @lumentechnologies and YouTube: /lumentechnologies.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lumen-technologies-to-present-at-the-bank-of-america-media-communications–entertainment-conference-301371352.html

SOURCE Lumen Technologies

Posted on

The Alkaline Water Company’s C-Store Sales Up 228% in Current Fiscal Year

The Alkaline Water Company’s C-Store Sales Up 228% in Current Fiscal Year

New Strategic DSDs and Distribution Centers Drive Growth

SCOTTSDALE, Ariz.–(BUSINESS WIRE)–
The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the “Company”), the country’s largest independent alkaline water company and The Clean Beverage Company™, is pleased to announce that this year’s sales in the all-important C-Store channel have more than doubled over the previous year. The Company attributes much of this growth to partnerships with several new major Direct-Store-Delivery providers and additional placements in six new distribution centers of legacy partners.

“Our C-store channel sales are beginning to grow significantly. Last month alone, we grew by almost 300% in c-store sales, making it by far our most successful month in the company’s history. This is before the full impact of any of our new DSDs or six new distribution centers has even been felt,” said Richard A. Wright, President and CEO of The Alkaline Water Company. “The Alkaline88 footprint continues to expand with each new distribution center added to our nationwide network. Recent additions to our network of distributors include Nassau Candy, Cooper Booth Wholesale, Hensley Beverage Company, Nevada Beverage Company, and National Convenience Distributors. Combined with our legacy partners, our network’s access now gives us the potential to service approximately 50,000 of the 150,000 convenience stores across the country. Between our traditional channels and C-stores, our single-serves are now available to more customers than ever before. Many of our single-serve SKUs, including our aluminum bottle and many of our flavored-infused waters, are on pace to significantly outperform their sales from last year. The C-store channel is a leader in bottled water sales with over $4.5 billion in sales last year, according to Convenience Store News. While we continue to see significant growth in our traditional channels, we anticipate that the convenience channel will meaningfully contribute to our fiscal year 2022 sales revenues.”

Alkaline88® is known for its superior hydration with a perfect 8.8pH balance. The brand was developed to deliver a Deliciously Smooth™ taste that encourages consumers to drink more and fully hydrate. The Company is dedicated to purity, quality, value, and taste. The water’s ingredient deck is simple, easy to understand, and free of buffers. Alkaline88 ionized water contains just two ingredients that customers trust — purified water and Pink Himalayan Rock Salt.

The Alkaline Water Company is The Clean Beverage Company™ making a difference in the water you drink and the world we share.

The Alkaline88® flagship brand of premium alkaline water is now available in 75,000 stores across all trades in the U.S. For more information, visit www.thealkalinewaterco.com.

About The Alkaline Water Company:

Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts our trademarked label “Clean Beverage.” Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. In 2021, The Alkaline Water Company was pleased to welcome Shaquille O’Neal to its board of advisors and to serve as the celebrity brand ambassador for the Alkaline88® and A88 Infused™ brands.

To purchase Alkaline88® and A88 Flavor Infused products online, visit us at www.alkaline88.com.

To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect with us on Facebook, Twitter, Instagram, or LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the following: that combined with the Company’s legacy partners, the Company’s network’s access now gives the Company the potential to service approximately 50,000 of the 150,000 convenience stores across the country; that many of the Company’s single-serve SKUs, including the Company’s aluminum bottle and many of the Company’s flavored-infused waters, are on pace to significantly outperform their sales from last year; and that the Company anticipates the convenience channel will meaningfully contribute to the Company’s fiscal year 2022 sales revenues.

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

The Alkaline Water Company Inc.

Jeff Wright

Director of Investor Relations

866-242-0240

[email protected]

Media

Jessica Starman

888-461-2233

[email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Food/Beverage Retail

MEDIA:

Logo
Logo
Posted on

Athleta Expands REI Co-op Partnership From Five to 135 Stores Nationwide and Online

Athleta Expands REI Co-op Partnership From Five to 135 Stores Nationwide and Online

Athleta commits to growth through investment in strategic wholesale partners

SAN FRANCISCO–(BUSINESS WIRE)–
Today, Athleta (NYSE: GPS) announced the expansion of a wholesale partnership with REI Co-op, bringing a curated selection of its product to 135 REI stores nationwide and online. As part of its growth plan to reach $2 billion in net sales by 2023, Athleta has committed to investing in new touchpoints to increase awareness and drive new customer acquisition.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005750/en/

The collection will include select styles of Athleta premium performance and lifestyle apparel and accessories, designed by women for women. Customers will be able to shop Athleta core lifestyle, hike and yoga bottoms, along with key tops and accessories. Additionally, REI will carry select extended sizing options from size 0-26 in hiking and fitness apparel designs in one quarter of all stores and on REI.com, bringing women even more inclusive sizing options and ways to shop.

“We’re constantly looking at new ways to bring Athleta to more customers and meet her where she is, which is an important component of our growth strategy,” said Mary Beth Laughton, President and CEO, Athleta. “This expanded partnership with REI is an example of how we can extend our reach through a like-minded brand and empower a new community of active women consumers.”

“We are thrilled to offer a wider selection of Athleta options, in more locations, to our customers,” said Krista Hildebrand, REI senior merchandising manager. “Athleta is an amazing brand offering many versatile apparel choices so customers can focus on enjoying the outdoors.”

Athleta is a purpose-driven brand with a mission to ignite a community of healthy, confident, active women and girls to reach their limitless potential. This partnership brings together two purpose-driven brands who share a belief in sustainable business practices and empowering women to enjoy active lifestyles.

To view the Athleta collection on REI’s website, visit rei.com/b/athleta

About Athleta:

A certified B Corporation, Athleta is a performance lifestyle brand with a mission of empowering a community of active women and girls. Athleta’s versatile premium performance lifestyle apparel is designed by women for women with inclusivity at its core. Founded in 1998, Athleta integrates performance and technical features across its collection to support women across their entire lifestyle – from yoga and training to travel and sleep. In 2016, the company launched Athleta Girl mirroring its signature performance in styles for the next generation. Based in San Francisco, CA and a Gap Inc. brand (NYSE: GPS), Athleta apparel is available at its over 200 retail stores across the United States, through its catalog, and at Athleta.com.

About REI:

REI is a specialty outdoor retailer, headquartered near Seattle. The nation’s largest consumer co-op, REI is a growing community of more than 20 million members who expect and love the best quality gear, inspiring expert classes and trips, and outstanding customer service. REI has 168 locations in 39 states and the District of Columbia. If you can’t visit a store, you can shop at REI.com, REI Outlet or the REI shopping app. REI isn’t just about gear. Adventurers can take the trip of a lifetime with REI’s active adventure travel company that runs more than 100 itineraries across the country. In many communities where REI has a presence, professionally trained instructors share their expertise by hosting beginner-to advanced-level classes and workshops about a wide range of activities. To build on the infrastructure that makes life outside possible, REI invests millions annually in hundreds of local and national nonprofits that create access to—and steward—the outdoor places that inspire us all.

Mya Walters (Athleta):

[email protected]

Courtney Gearhart (REI):

[email protected]

KEYWORDS: United States North America California Washington

INDUSTRY KEYWORDS: Retail Online Retail Specialty Fashion

MEDIA:

Logo
Logo
Logo
Logo
Posted on

10X Capital Leadership Purchases Additional Shares In REE Automotive

10X Capital Leadership Purchases Additional Shares In REE Automotive

REE (Nasdaq: REE) SPAC sponsor completes open market purchases

NEW YORK–(BUSINESS WIRE)–
10X Capital today announced that Hans Thomas, CEO, and David Weisburd, COO, each made filings with the SEC reporting the purchase of additional shares in REE Automotive (NASDAQ: REE) common stock totaling approximately $2 million, through open market purchases made in September 2021.

Mr. Thomas reported the purchase of: 161,037 shares at an average price of $5.81 on September 1, 2021; and 60,963 shares at an average price of $5.66 on September 2, 2021; for a total of 222,000 shares.

Mr. Weisburd reported the purchase of 123,908 shares at an average price of $5.97 on September 1, 2021.

The SEC filings are available on EDGAR, and linked below:

Hans Thomas:

https://www.sec.gov/Archives/edgar/data/1828707/000121390021046457/xslF345X03/ownership.xml

David Weisburd:

https://www.sec.gov/Archives/edgar/data/1828663/000121390021046466/xslF345X03/ownership.xml

About 10X CAPITAL

10X Capital is a venture capital and investment firm at the nexus of Wall Street and Silicon Valley, aligning institutional capital with high growth ventures. For more information visit www.10xcapital.com.

10X Capital Venture Acquisition Corp (formerly Nasdaq: VCVC), is 10X Capital’s Special Purpose Acquisition Company, focused on high growth technology companies, and was formed for the purpose of entering into a business combination with one or more businesses. For more information visit www.10xspac.com.

Max Staedtler

10X Capital

One World Trade Center, 85th Floor

New York, NY 10007

(212) 257-0069

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Finance Hardware Alternative Vehicles/Fuels Automotive Other Automotive Professional Services Technology Other Technology

MEDIA:

Posted on

AbbVie to Present Data From Its Migraine Portfolio at the 2021 International Headache Congress

–Results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluate the safety and tolerability of oral atogepant for the preventive treatment of migraine

–Data from the observational cross-sectional UNIVERSE study highlight the real-world effectiveness and patient satisfaction of ubrogepant in acute migraine

–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine

–These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum

PR Newswire

NORTH CHICAGO, Ill., Sept. 8, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that data from its migraine portfolio will be presented at the International Headache Congress 2021, held jointly this year by the International Headache Society and the European Headache Federation, from September 8-12. The company will share a total of 23 abstracts, including two oral presentations and one abstract lecture.  

“We continue to conduct research that seeks to provide additional insights into the safety, efficacy and clinical utility of our approved and investigational migraine therapies,” said Michael Gold, M.D., vice president, neuroscience development, AbbVie. “The data we’re presenting are a result of AbbVie’s ongoing commitment to driving progress in the migraine community.”

Among the new data being presented are results from an open-label, multicenter extension to the pivotal Phase 3 ADVANCE trial evaluating the long-term safety and tolerability of atogepant, an investigational, orally administered calcitonin gene-related peptide receptor antagonist developed for the preventive treatment of migraine over 40 weeks. Researchers will also share data from the Phase 1, single-center, open-label, multiple-dose study assessing the potential for pharmacokinetic drug-drug interactions between atogepant and topiramate; the observational cross-sectional UNIVERSE study examining real-world effectiveness and patient satisfaction of ubrogepant for acute migraine treatment; and the POLARIS study, a retrospective claims data analysis examining the real-world treatment patterns of oral migraine preventive medication by pharmacologic class in people with migraine.

Additional presentations will focus on the efficacy of atogepant for the preventive treatment of migraine based on further analyses from the ADVANCE trial, the safety and tolerability of investigational ubrogepant as a potential acute treatment for perimenstrual migraine, and real-world evidence regarding the safety and efficacy of CGRP monoclonal antibody therapy added to BOTOX® (onabotulinumtoxinA) for migraine prevention in adult patients with chronic migraine. Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluating the use of BOTOX® for chronic migraine will also be presented.

AbbVie abstracts and presentation details for IHC 2021 are outlined below.


Abstract Title


Presentation Details


All times CT


Atogepant

Long-Term Safety and Tolerability of Atogepant 60 mg Following Once Daily Dosing Over 1 Year for the Preventive Treatment of Migraine

ePoster

September 11, 2021

3:42 a.m. CT

Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Prevention of Migraine

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Oral Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Daily Dosing of Oral Atogepant Improved Patient-Reported Measures of Quality of Life, Activity Impairment, and Headache Impact in a 52-week Trial

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Evaluation of The Long-Term Safety and Tolerability of Oral Atogepant 60 mg Once Daily for Preventive Treatment of Migraine: A Phase 3, 40-Week, Multicenter Extension to the ADVANCE Trial

Abstract Lecture

September 12, 2021

2:45-2:55 a.m. CT

Evaluation of the Pharmacokinetic Interaction and Safety of Coadministered Atogepant and Topiramate

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT


Ubrogepant

Preventive Oral Migraine Treatment Utilization Patterns (POLARIS STUDY): A Retrospective Claims Data Analysis

ePoster

September 11, 2021

4:51 a.m. CT

COmbining UbRogepAnt and Preventives for miGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-World Evidence

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Ubrogepant Users’ Experience – Patients on Ubrogepant, Characteristics and Outcomes (UNIVERSE STUDY)

Oral Presentation

September 11, 2021

3:20 a.m. CT

A Novel Approach to Defining Success in the Acute Treatment of Migraine: Demonstrating Therapeutic Benefit at 1 Hour Post-Dose in the Pooled ACHIEVE I and ACHIEVE II Trials

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results From the ACHIEVE I and ACHIEVE II Trials

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Ubrogepant Treatment When Pain Is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe Pain

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT


BOTOX

®
(onabotulinumtoxinA)

Real-World Evidence for Control of Patients With Chronic Migraine Who Received Calcitonin Gene‒Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Optimal Acute Treatment Is Associated With Productivity Gains in People With Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

ePoster

September 11, 2021

3:39 a.m. CT

Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine

ePoster

September 11, 2021

4:12 a.m. CT

Impact of Prior Monthly Headache Days on Migraine-Related Quality of Life: Results From the CaMEO Study

ePoster (on-demand only)

September 8, 2021

1 a.m.-1:15 p.m. CT

Characterizing Preventive Treatment Gaps in Migraine: Results From the CaMEO Study

Oral Presentation

September 10, 2021

8:15 a.m. CT

About Atogepant
Atogepant is an investigational, orally administered, CGRP receptor antagonist (gepant) specifically developed for the preventive treatment of migraine. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks, and selective CGRP receptor antagonists confer clinical benefit in migraine. Atogepant is currently under review by the U.S. FDA.

About BOTOX

®

BOTOX® was first approved by the FDA in 1989 for two rare eye muscle disorders – blepharospasm and strabismus in adults. Today, BOTOX® is FDA-approved for 12 therapeutic indications, including Chronic Migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults, cervical dystonia, adult and pediatric spasticity, severe underarm sweating (axillary hyperhidrosis), and pediatric detrusor overactivity associated with a neurologic condition.

BOTOX® (onabotulinumtoxinA) Important Information in the United States

Indications
BOTOX® is a prescription medicine that is injected into muscles and used:

  • To treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken
  • To treat leakage of urine (incontinence) in adults 18 years and older with overactive bladder caused by a neurologic disease who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication
  • To treat overactive bladder due to a neurologic disease in children 5 years of age and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken
  • To prevent headaches in adults with chronic migraine who have 15 or more days each month with headache lasting 4 or more hours each day in people 18 years or older
  • To treat increased muscle stiffness in people 2 years of age and older with spasticity
  • To treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older
  • To treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years of age and older

BOTOX® is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.

It is not known whether BOTOX® is safe and effective to prevent headaches in patients with migraine who have 14 or fewer headache days each month (episodic migraine).

BOTOX® has not been shown to help people perform task-specific functions with their upper limbs or increase movement in joints that are permanently fixed in position by stiff muscles.

It is not known whether BOTOX® is safe and effective for severe sweating anywhere other than your armpits.

IMPORTANT SAFETY INFORMATION

BOTOX
® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX®:

  • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months
  • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing

There has not been a confirmed serious case of spread of toxin effect away from the injection site when BOTOX® has been used at the recommended dose to treat chronic migraine, severe underarm sweating, blepharospasm, or strabismus.

BOTOX® may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX®. If this happens, do not drive a car, operate machinery, or do other dangerous activities.

Do not receive BOTOX
® if you: are allergic to any of the ingredients in BOTOX® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

Do not receive BOTOX
® for the treatment of urinary incontinence if you: have a urinary tract infection (UTI) or cannot empty your bladder on your own and are not routinely catheterizing. Due to the risk of urinary retention (not being able to empty the bladder), only patients who are willing and able to initiate catheterization post treatment, if required, should be considered for treatment.

Patients treated for overactive bladder:
In clinical trials, 36 of the 552 patients had to self-catheterize for urinary retention following treatment with BOTOX® compared to 2 of the 542 treated with placebo. The median duration of post-injection catheterization for these patients treated with BOTOX® 100 Units (n = 36) was 63 days (minimum 1 day to maximum 214 days) as compared to a median duration of 11 days (minimum 3 days to maximum 18 days) for patients receiving placebo (n = 2). Patients with diabetes mellitus treated with BOTOX® were more likely to develop urinary retention than nondiabetics.

Adult Patients treated for overactive bladder due to neurologic disease:
In clinical trials, 30.6% of patients (33/108) who were not using clean intermittent catheterization (CIC) prior to injection, required catheterization for urinary retention following treatment with BOTOX® 200 Units as compared to 6.7% of patients (7/104) treated with placebo. The median duration of post-injection catheterization for these patients treated with BOTOX® 200 Units (n = 33) was 289 days (minimum 1 day to maximum 530 days) as compared to a median duration of 358 days (minimum 2 days to maximum 379 days) for patients receiving placebo (n = 7). Among patients not using CIC at baseline, those with MS were more likely to require CIC post injection than those with SCI.

The dose of BOTOX
® is not the same as, or comparable to, another botulinum toxin product.

Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, dizziness, or feeling faint. Get medical help right away if you experience symptoms; further injection of BOTOX® should be discontinued.

Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig’s disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing from typical doses of BOTOX®.

Tell your doctor if you have any breathing-related problems. Your doctor may monitor you for breathing problems during treatment with BOTOX® for spasticity or for detrusor overactivity associated with a neurologic condition. The risk of developing lung disease in patients with reduced lung function is increased in patients receiving BOTOX®.

Cornea problems have been reported. Cornea (surface of the eye) problems have been reported in some people receiving BOTOX® for their blepharospasm, especially in people with certain nerve disorders. BOTOX® may cause the eyelids to blink less, which could lead to the surface of the eye being exposed to air more than is usual. Tell your doctor if you experience any problems with your eyes while receiving BOTOX®. Your doctor may treat your eyes with drops, ointments, contact lenses, or with an eye patch.

Bleeding behind the eye has been reported. Bleeding behind the eyeball has been reported in some people receiving BOTOX® for their strabismus. Tell your doctor if you notice any new visual problems while receiving BOTOX®.

Bronchitis and upper respiratory tract infections (common colds) have been reported. Bronchitis was reported more frequently in adults receiving BOTOX® for upper limb spasticity. Upper respiratory infections were also reported more frequently in adults with prior breathing-related problems with spasticity. In pediatric patients treated with BOTOX® for upper limb spasticity, upper respiratory tract infections were reported more frequently. In pediatric patients treated with BOTOX® for lower limb spasticity, upper respiratory tract infections were not reported more frequently than placebo.

Autonomic dysreflexia in patients treated for overactive bladder due to neurologic disease. Autonomic dysreflexia associated with intradetrusor injections of BOTOX® could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy. In clinical trials, the incidence of autonomic dysreflexia was greater in adult patients treated with BOTOX® 200 Units compared with placebo (1.5% versus 0.4%, respectively).

Tell your doctor about all your medical conditions, including if you: have or have had bleeding problems; have plans to have surgery; had surgery on your face; weakness of forehead muscles; trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; have symptoms of a urinary tract infection (UTI) and are being treated for urinary incontinence (symptoms of a urinary tract infection may include pain or burning with urination, frequent urination, or fever); have problems emptying your bladder on your own and are being treated for urinary incontinence; are pregnant or plan to become pregnant (it is not known if BOTOX® can harm your unborn baby); are breastfeeding or plan to (it is not known if BOTOX® passes into breast milk).

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX®in the past.

Tell your doctor if you received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin®in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

Other side effects of BOTOX
® include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, dry eyes; drooping eyebrows; and upper respiratory tract infection. In adults being treated for urinary incontinence, other side effects include urinary tract infection and painful urination. In children being treated for urinary incontinence, other side effects include urinary tract infection and bacteria in the urine. If you have difficulty fully emptying your bladder on your own after receiving BOTOX®, you may need to use disposable self-catheters to empty your bladder up to a few times each day until your bladder is able to start emptying again.

For more information refer to the Medication Guide or talk with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see BOTOX
® full Product Information, including Boxed Warning and Medication Guide.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About UBRELVY® (ubrogepant) in the United States

UBRELVY
® (ubrogepant) is an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine with or without aura in adults that is an option for a wide range of patients who experience migraine attacks. UBRELVY® is the first pill of its kind to directly block CGRP, a protein released during a migraine attack, from binding to its receptors.

IMPORTANT SAFETY INFORMATION

Who should not take UBRELVY® (ubrogepant)?
Do not take UBRELVY® if you are taking medicines known as strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, itraconazole.

What should I tell my healthcare provider before taking UBRELVY®?
Tell your healthcare provider about all your medical conditions, including if you:

  • Have liver problems
  • Have kidney problems
  • Are pregnant or plan to become pregnant
  • Are breastfeeding or plan to breastfeed

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider can tell you if it is safe to take UBRELVY® with other medicines.

What are the most common side effects of UBRELVY®?
The most common side effects are nausea (4%) and sleepiness (3%). These are not all of the possible side effects of UBRELVY®.

What is UBRELVY® (ubrogepant)?
UBRELVY® is a prescription medicine used for the acute treatment of migraine attacks with or without aura in adults. UBRELVY® is not used to prevent migraine headaches.

Please see full Prescribing Information.

Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Migraine
Impacting one billion people worldwide, migraine is a neurological disease with recurring attacks that causes pain and other disabling symptoms. However, migraine can be treatable. At AbbVie, we are committed to empowering people in their pursuit of migraine freedom. We advance science that enables healthcare providers to care for people impacted across the spectrum of migraine. Through education and partnerships with the migraine community, we strive to help those with migraine navigate barriers to care, access effective treatments and reclaim their lives.

About AbbVie in Neuroscience
At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie’s Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders, including Alzheimer’s disease, bipolar I disorder, major depressive disorder, migraine, Parkinson’s disease, spinal cord injuries, post-stroke spasticity, schizophrenia, stroke and others.

We have a strong investment in neuroscience research, with our Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience Discovery site in Ludwigshafen, Germany, where our research and resilience in these challenging therapeutic areas is yielding a deeper understanding of the pathophysiology of neurological and psychiatric disorders, and identifying targets for potential disease-modifying therapeutics aimed at making a difference in people’s lives.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @AbbVie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie’s acquisition of Allergan plc (“Allergan”), failure to promptly and effectively integrate Allergan’s businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s
 
2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

 

Cision View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-data-from-its-migraine-portfolio-at-the-2021-international-headache-congress-301371379.html

SOURCE AbbVie

Posted on

Carvana Arrives in Carson City with The New Way to Buy a Car®

Carvana Arrives in Carson City with The New Way to Buy a Car®

Carvana Continues Silver State Expansion With Launch in State Capital

CARSON CITY, Nev.–(BUSINESS WIRE)–Carvana (NYSE: CVNA) the leading e-commerce platform for buying and selling used cars, is now offering as-soon-as-next-day touchless home delivery to Carson City area residents. Customers can shop 45,000 used cars for sale, secure auto financing or use the car loan calculator, purchase, trade in, and schedule as-soon-as-next-day vehicle delivery in as little as five minutes. Customers can also sell their current vehicle to Carvana and receive a real offer just as quickly, without even purchasing a vehicle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005381/en/

Carvana Brings The New Way to Buy a Car® to Carson City. (Photo: Business Wire)

Carvana Brings The New Way to Buy a Car® to Carson City. (Photo: Business Wire)

Carvana customers can save valuable time and money with The New Way to Buy a Car® by skipping the dealership and shopping online. As the pioneer of online car buying, Carvana gives customers a high-definition, 360-degree virtual tour of every vehicle, inside and out. Carvana vehicles have passed a rigorous 150-point inspection, have never been in a reported accident and have no frame damage. Features, imperfections, and updated information about open safety recalls are listed on every car’s vehicle description page.

All 45,000+ vehicles in Carvana’s national inventory come with a seven-day return policy; an upgrade to the traditional test-drive. This ensures customers have the right amount of time to determine if the vehicle fits their needs. By living with their vehicle for a week, customers can do everything from test out the fuel efficiency of their newly purchased crossover on a weekend trip to Reno, or simply take it for a spin along the historic Kit Carson trail and explore the city’s rich history from the comfort of a new ride.

Customers looking to make a change can also trade in or sell a vehicle by simply entering their VIN or license plate number on Carvana.com, answering a few questions, and Carvana can pick the vehicle up and bring them a check, as soon as the next day.

“With the ability to shop thousands of cars online, at great prices, with as-soon-as-next-day delivery, we’re confident Carson City residents will embrace the ease and convenience that comes with The New Way to Buy a Car®,” said Ernie Garcia, Carvana founder and CEO.

Carvana now offers as-soon-as-next-day vehicle delivery to customers in 303 cities across the U.S.

About Carvana (NYSE: CVNA)

Founded in 2012 and based in Phoenix, Carvana’s (NYSE: CVNA) mission is to change the way people buy and sell cars. By removing the traditional dealership infrastructure and replacing it with technology and exceptional customer service, Carvana offers consumers an intuitive and convenient online car buying, selling, and financing platform. Carvana.com enables consumers to quickly and easily shop more than 45,000 vehicles, finance, trade in or sell their current vehicle to Carvana, sign contracts, and schedule as-soon-as-next-day delivery or pickup at one of Carvana’s patented, automated Car Vending Machines. Carvana is a Fortune 500 company, providing as-soon-as-next-day delivery to customers in over 300 U.S. markets.

For further information on Carvana, please visit www.carvana.com, or connect with us on Facebook, Instagram, Twitter or the Carvana Blog.

Carvana

Amy O’Hara

[email protected]

KEYWORDS: Nevada United States North America

INDUSTRY KEYWORDS: Online Retail Retail Other Automotive General Automotive Automotive

MEDIA:

Logo
Logo
Photo
Photo
Carvana Brings The New Way to Buy a Car® to Carson City. (Photo: Business Wire)